Medilinks.org

 
Health News About Us Health Topics Country Links

HIV/AIDS

 

Anti-Retroviral Drugs Used In HIV/AIDS

This table summarises information about HIV drugs including the latest prices at which antiretrovirals are being offered to developing countries, and the terms of the offers. Some of these offers are being made through the UNAIDS Accelerating Access Initiative; others are being offered through programmes established by the companies themselves. This table will be regularly updated as more information becomes available. View treatment and cost options: Option 1, Option 2, Option 3 -2002 | Option 1, Option 2, Option 3. - 2001

Drug

Special Provisions*

Discount* Price

Formulary

Standard Dosage

Generic Alternative

Protease Inhibitors (PI)

Agenerase

amprenavir

 

discounted by 50% from the wholesale price $16.80 per day ($6,132.00 annually) to

$8.70 per day,
$3175 per year

Available as 50 and 150 mg soft-gelatin capsules.

eight 150 mg capsules (1,200 mg) every 12 hours  twice daily

16 capsules a day

 

Crixivan

indinavir 

Africa
Romania
Haiti
Brazil

Available to NGOs and company health plans, as well as govts

$600 per year


200mg


400mg

The standard dose is two 400 mg capsules every 8 hours. It should be taken with water, and without food or with a very low-fat light meal and at least 1 hour before or 2 hours after a regular meal.

6 capsules a day

 

Fortovase

saquinavir 

also called:
soft-gel cap

Available to least developed nations at negotiable prices

- Roche is seeking to offer the drug at cost and offer research grants to those providing clinical care

c. $1300 if dosed once daily with ritonavir, or $2400 if dosed at 1200mg three times daily


 200 mg

1,200 mg (six 200 mg capsules) every 8 hours.

18 capsules a day

none

Invirase

saquinavir  

also called:
hard-gel cap



Top

Available to least developed nations at negotiable prices

- Roche is seeking to offer the drug at cost and offer research grants to those providing clinical care

c. $1300 if dosed once daily with ritonavir, or $2400 if dosed at 1200mg three times daily

600 mg (three 200 mg capsules) every 8 hours

12 capsules a day.

 

Kaletra

lopinavir
/ ritonavir 

Africa

(available to private sector or company health plans and NGOs, as well as govts)

c.$1,000 per year

Available in capsule form. Each contains 133 mg of lopinavir and 33 mg of ritonavir.

Also available in oral solution 100mg/ml

3 capsules twice a day (approx 500mg of drug)

6 capsules daily

5 ml oral solution twice daily

None

Norvir

ritonavir













Top

Africa

(available to private sector or company health plans and NGOs, as well as govts)

c. $1,000 per year


 100 mg tab


80mg/ml oral solution

six 100 mg capsules (600 mg) every 12 hours. 

12 capsules daily

or

7.5 ml (1 ˝ teaspoons twice daily )

India

Viracept

nelfinavir 

 

 

 


Top

 

Average cost $5650 pa

Price will be reduced by 15% , but only as a rebate bringing it down to

$4807 per year

 
250mg tablet

50mg oral powder

Three 250 mg tablets (750 mg) every 8 hours with food (a meal or light snack).

 

6 tablets a day

 

Powder has 50mg per 1g of powder. Used in children or those who have difficulty swallowing

 

 

Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)

Rescriptor

delavirdine

 

not offered as discounted

Wholesale price $7.60 per day ($2,696 annually


 100mg tab

Four 100 mg tablets  every 8 hours, 3 times daily

12 capsules a day

 

Sustiva

efavirenz

 

Africa
Romania
Haiti
Brazil

Available to NGOs and company health plans, as well as govts

$500 per year

200 mg capsules

Three 200 mg capsules once a day

 

Viramune


nevirapine 


Top

Maternal/infant treatment free to all non-EU countries

(also excludes USA, Canada, NZ, Australia, Japan, Switzerland, Norway, Iceland)

Free as two doses for mother and infant treatment

$1.22 per day for adult dosing ($445 p.a)


 200mg

One 200 mg tablet twice daily (every 12 hours)

India: Cipla (Nevimune$340 p.a)

Hetero ($202)

 

Nucleoside Reverse Transcriptase Inhibitors (NRTIs) 

Combivir

zidovudine / lamivudine 

Developing countries - govts, NGOs and workplace initiatives where suitable medical infrastructure exists, via UNAIDSAccelerating Access Initiative

$2 per day

$730 per year


Contains 300 mg of Retrovir plus 150 mg of Epivir

One pill twice a day (every twelve hours)

2 capsules a day

Brazil

India
Cipla - $635
Hetero - $293

Epivir

lamivudine

Also called: 3TC 

 

 


Top

Developing countries - govts, NGOs and workplace initiatives where suitable medical infrastructure exists, via UNAIDSAccelerating Access Initiative

58 cents per day

$212 per year


 150 mg tab


10mg per ml (50mg in a teaspoon approx 5ml).

150 mg every twelve hours for adults over 50kg

2mg /kg every twelve hours for adults 50kg or less

(see Combivir)

Brazil

India
Cipla $190
Hetero $98

Hivid

zalcitabine 

also called:
ddC 

 

Available at cost

retail prices vary from $150 - $200 per 100 tabs

approx
which costs from $3285 - $4380


 0.375mg


0.75mg

0.75 mg every 8 hours three times a day 

(2.25 mg of Hivid per day divided into three doses)

Brazil

Retrovir

zidovudine

also called:
AZT














Top

Developing countries - govts, NGOs and workplace initiatives where suitable medical infrastructure exists, via UNAIDSAccelerating Access Initiative

 95% reduction on "average global price"

was $2000 pa in 1997 which equates to

$100 per year discounted


 100mg

 300mg 

50mg per ml syrup

300 mg every 12 hours

 (also see combivir)

Brazil

India

Videx

didanosine 

also called:ddI



















Top

Not available to private sector/company health plans

80 cents per day

$0.80 per day

$292 per year


25mg tabs


50 mg


100 mg


150 mg

2 tablets every twelve hours (twice a day)

Not patented in Africa

Thailand

Brazil

India

Zerit

stavudine

aslo called: d4T 

Not available to private sector/company health plans

15 cents a day/$54 per year


15 mg capsules


20 mg


 40 mg

Adult over 60kg - 40mg every twelve hours

Adult under 60kg – 30 mg every twelve hours

Thailand

Brazil

India
Cipla $70
Hetero $47

Ziagen

abacavir 


Top

Developing countries - govts, NGOs and workplace initiatives where suitable medical infrastructure exists, via UNAIDSAccelerating Access Initiative

It was hoped that there would be a 95% reduction on "average global price" which
was $3000 pa in 1998 and
equates to $150 per year

However Glaxo have announced a reduction from $10.68 per day ($3898 per yr) to $3.80 per day ($1387 per yr)

300 mg tablet and an oral solution

20 mg/ml

one 300 mg tablet every 12 hours or twice daily

none
INFORMATION

HAART

Protease Inhibitors

Agenerase (amprenavir)

Crixivan (indinavir)

Fortovase (saquinavir)

Invirase (saquinavir)

Kaletra (lopinavir / ritonavir)

Norvir (ritonavir)

Viracept (nelfinavir)


Non-Nucleoside Reverse Transcriptase Inhibitors

Rescriptor (delavirdine)

Sustiva (efavirenz)

Viramune (nevaripine)


Nucleoside Reverse Transcriptase Inhibitors

Combivir (ziduvidine / lamuvudine)

Epivir (lamuvidine)

Hivid (zalcatibine)

Retrovir (ziduvidine)

Videx (didanosine)

Zerit (stavudine)

Ziagen (abacavir)

 

DRUGS & TREATMENT

 

AIDS UPDATES
2002
2001

 

Special Coverage: XIV International Conference on AIDS Barcelona, Spain, 7-12 July 2002 

 
Research on the web
Transmission of HIV-2
The Lancet Infectious Disease
11/15/2003
HIV-positive mothers in Uganda resort to breastfeeding
The Lancet Medical Journal
8/20/2003
Education and debate: Ethics guidance for HIV prevention trials
BMJ
8/19/2003
Virology: Weapons of mutational destruction
AIDScience
8/19/2003
Predicting the public health impact of antiretrovirals: preventing HIV in developing countries
AIDScience Vol. 3, No. 11, 2003
6/24/2003
Examining the hypothesis that sexual transmission drives Africa’s HIV epidemic
AIDScience Vol. 3, No. 10, 2003
6/24/2003
Preventing HIV- Time to get serious about changing behaviour
BMJ 2003;326:1342-1343 (21 June)
6/24/2003
Antiretroviral treatment in developing countries: the peril of neglecting private providers
BMJ 2003;326:1382-1384 (21 June)
6/24/2003
Back to basics in HIV prevention: focus on exposure
BMJ
6/24/2003
Public policies and the orphans of AIDS in Africa
BMJ
6